2seventy Bio, Inc.

Bluebird Bio, Inc.

Regeneron Pharmaceuticals, Inc.

Helixmith Co., Ltd

Kevin Friedman

Richard Morgan

Molly Reed Perkins

Seung Shin Yu

Jae-Gyun Jeong

Jin-A Chae

Byoung Ryu

Dawn Maier

The invention provides compositions and methods for manufacturing adoptive cell therapies. In particular embodiments, the invention provides methods of harvesting populations of cells, isolating and activating PBMCs, expanding T cells, and administering the T cell therapeutic to a subject in need thereof.

Methods for manufacturing adoptive cell therapies

The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.

Anti-BCMA CAR antibodies, conjugates, and methods of use

The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.

CD79A chimeric antigen receptors

The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.

BCMA chimeric antigen receptors

The invention provides improved T cell compositions and methods for manufacturing T cells. More particularly, the invention provides methods of T cell manufacturing that result in adoptive T cell immunotherapies with improved survival, expansion, and persistence in vivo.

Methods of making T cell compositions

T cell compositions

The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.

Anti-Sialyl Tn chimeric antigen receptors

Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.

Growing community of inventors

Melrose, MA, United States of America

Kevin Friedman